Diabetes MellitusDiabesityDayNCT06680674
Multinational Point Prevalence Study on the Management of Diabesity in Hospitals
An observational study of Diabetes Mellitus and Obesity, run by Medical University of Vienna at 8 sites in 8 countries.
Trial summary
Diabetes related to obesity ("diabesity") is becoming increasingly prevalent. Hospitalizations among people with diabetes are frequent and glycaemic control is often suboptimal during these stays. However, the pharmacological treatment of diabesity has made significant progress in recent years. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetes Mellitus, Obesity
- What is being tested?
- Routine care for people with diabetes, with or without obesity, in the hospital setting
- How many people
- 207 participants
- Where
- 8 sitesin 8 countries
- Study dates
- 13 Nov 2024to 2 Sep 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adults (age ≥ 18 years) with diabetes who are admitted to an internal medicine ward of a participating medical centre at the time of the study
Who may be able to join
- Hospitalized at the time of the survey for any cause
- Diabetes diagnosis (Known / documented in medical history or newly diagnosed using ADA diagnostic criteria)
- Age ≥ 18 years
- Written informed consent
Who cannot join
- Patients in wards and units other than internal medicine wards (such as outpatient areas, emergency departments, skilled nursing and intensive care units, etc.)
- Paediatric patients (Age < 18 years)
- Patients without a diabetes diagnosis
Trial locations and contacts
8 sites in 8 countries.
8 sites in 8 countries
Greece1 site
Hippokration General Hospital, Aristotle University of Thessaloniki
Thessaloniki
Turkey (Türkiye)1 site
Kanuni Sultan Suleyman Training and Research Hospital
Istanbul
About this study
Official title: Multinational Cross-sectional Review of Diabetes and Obesity Management in Hospitals Across Europe: The DIABESITY Survey
Diabetes related to obesity ("diabesity") is becoming increasingly prevalent. Hospitalizations among people with diabetes are frequent and glycaemic control is often suboptimal during these stays.
However, the pharmacological treatment of diabesity has made significant progress in recent years.
Read more
The objective of this study is to assess the management of diabesity in the international hospital setting. Aims include:
- to determine the prevalence of causes and duration of hospitalization
- to investigate the treatments used
- to determine individual metabolic control achived This is a cross-sectional multi-centre study in which researchers will conduct a one-day point prevalence assessment in internal medicine wards.
- Conditions
- Diabetes Mellitus, Obesity
- Being tested
- Routine care for people with diabetes, with or without obesity, in the hospital setting
- Medical subject headings
- Diabetes Mellitus, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Routine care for people with diabetes, with or without obesity, in the hospital settingOther
Routine care for people with diabetes, with or without obesity, in the hospital setting, including routine pharmacological treatment for diabetes and obesity.
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of point-of-care glucose values
Mean number of point-of-care glucose measurements during hospitalization
Measured: 3 days
Secondary outcomes (1)
Severe hypoglycaemia
Severe hypoglycaemia during admission (glucose <40mg/dL)
Measured: From day of admission to the day of data collection, i.e., November 14, 2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Nov 2024
- Study start13 Nov 2024
- Primary completion25 Mar 2025
- Study completion2 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes MellitusStudies of the same condition, open and under way.
- More trials run by Medical University of ViennaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 207 participants (actual)
Sponsor and investigators
- Lead sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Collaborators
- Hospital de Cascais Dr. José de Almeida (Portugal), Centre Hospitalier Universitaire Sétif, Service Médecine Interne (Algeria), Rabin Medical Center, Hospital Regional de Malaga, Charles University, Czech Republic, University Hospital Bratislava, Complejo Hospitalario de Especialidades Juan Ramón Jimenez, Medical University Innsbruck, Aristotle University Of Thessaloniki, Rostov State Medical University, Hospital Marina Baixa, Riga East Clinical University Hospital, University Hospital, Aachen, San Raffaele University Hospital, Italy, Kanuni Sultan Suleyman Training and Research Hospital
- Responsible party
- Principal investigator, Ann-Kristin Porth, Medical University of Vienna
- Investigators
- Alexandra Kautzky-Willer, Prof, Study director, Medical University of Vienna
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06680674
- Sponsor's protocol ID
- EK 1828/2024
- Acronym
- DiabesityDay
- Status last verified
- Sep 2025
- First submitted
- 6 Nov 2024
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Patient data will only be shared in aggregated form.
Study at a glance
From the registry record, last updated by the sponsor on 7 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Multinational Cross-sectional Review of Diabetes and Obesity Management in Hospitals Across Europe: The DIABESITY Survey
- ClinicalTrials.gov ID
- NCT06680674
- Acronym / sponsor ID
- DiabesityDay / EK 1828/2024
- Conditions
- Diabetes Mellitus, Obesity
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 207 participants (actual)
- Lead sponsor
- Medical University of ViennaUniversity, hospital or other
- Collaborators
- Hospital de Cascais Dr. José de Almeida (Portugal), Centre Hospitalier Universitaire Sétif, Service Médecine Interne (Algeria), Rabin Medical Center, Hospital Regional de Malaga, Charles University, Czech Republic, University Hospital Bratislava, Complejo Hospitalario de Especialidades Juan Ramón Jimenez, Medical University Innsbruck, Aristotle University Of Thessaloniki, Rostov State Medical University, Hospital Marina Baixa, Riga East Clinical University Hospital, University Hospital, Aachen, San Raffaele University Hospital, Italy, Kanuni Sultan Suleyman Training and Research Hospital
- Study start
- 13 Nov 2024 (actual)
- Primary completion
- 25 Mar 2025 (actual)
- Study completion
- 2 Sep 2025 (actual)
- First posted
- 8 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Diabetes related to obesity ("diabesity") is becoming increasingly prevalent. Hospitalizations among people with diabetes are frequent and glycaemic control is often suboptimal during these stays.
However, the pharmacological treatment of diabesity has made significant progress in recent years.
The objective of this study is to assess the management of diabesity in the international hospital setting. Aims include:
- to determine the prevalence of causes and duration of hospitalization
- to investigate the treatments used
- to determine individual metabolic control achived This is a cross-sectional multi-centre study in which researchers will conduct a one-day point prevalence assessment in internal medicine wards.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Adults (age ≥ 18 years) with diabetes who are admitted to an internal medicine ward of a participating medical centre at the time of the study
Key inclusion criteria (4 listed)
- Hospitalized at the time of the survey for any cause
- Diabetes diagnosis (Known / documented in medical history or newly diagnosed using ADA diagnostic criteria)
- Age ≥ 18 years
- Written informed consent
Key exclusion criteria (3 listed)
- Patients in wards and units other than internal medicine wards (such as outpatient areas, emergency departments, skilled nursing and intensive care units, etc.)
- Paediatric patients (Age < 18 years)
- Patients without a diabetes diagnosis
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Routine care for people with diabetes, with or without obesity, in the hospital settingRoutine care for people with diabetes, with or without obesity, in the hospital setting, including routine pharmacological treatment for diabetes and obesity. | Other | – |
Primary outcome
Number of point-of-care glucose values
Time frame: 3 days
Mean number of point-of-care glucose measurements during hospitalization
1 secondary outcome
Severe hypoglycaemia
Time frame: From day of admission to the day of data collection, i.e., November 14, 2024
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Oct 2026.
- Individual participant dataSharing planned: No. Patient data will only be shared in aggregated form.
Related trials for Diabetes Mellitus
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alexandra Kautzky-Willer, Prof study director
Medical University of Vienna
8 sites in 8 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes Mellitus and Obesity, run by Medical University of Vienna at 8 sites in 8 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in Austria, Czechia, Germany, Greece, Israel and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of point-of-care glucose values (time frame: 3 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Oct 2026.